Finance

Lists
1177:HKG
Sino Biopharmaceutical Ltd
HK$ ५.२५
-०.३८%
(-०.०२०) 1D
अक्टोबर १६, १६:०८:१४ GMT+८  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1177...
Open
HK$ ५.४०
High
HK$ ५.५०
Low
HK$ ५.१४
Mkt. cap
९८.०९ अरब
Avg. vol.
६.९३ करोड
Volume
८.३९ करोड
Dividend
२.२९%
Quarterly dividend
HK$ ०.०३
Ex-dividend date
२०२५ अगस्ट २९
P/E ratio
३३.८६
52-wk high
HK$ ७.७९
52-wk low
HK$ ४.१९
EPS
HK$ ०.१६
Shares outstanding
१२.६४ अरब
No. of employees
२३ हजार
Open
HK$ ५.४०
High
HK$ ५.५०
Low
HK$ ५.१४
Mkt. cap
९८.०९ अरब
Avg. vol.
६.९३ करोड
Volume
८.३९ करोड
Dividend
२.२९%
Quarterly dividend
HK$ ०.०३
Ex-dividend date
२०२५ अगस्ट २९
P/E ratio
३३.८६
52-wk high
HK$ ७.७९
52-wk low
HK$ ४.१९
EPS
HK$ ०.१६
Shares outstanding
१२.६४ अरब
No. of employees
२३ हजार
News stories
From web sources and news partners
Profile
Sino Biopharmaceutical Limited, shortly SBP Group, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China 25 Index in 2020. The Group’s principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. and invoX Pharma Limited. Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia. Wikipedia
About Sino Biopharmaceutical Ltd
CEOLi Yi
Employees२२.८ हजार
Founded२०००
Headquarters-
Sector-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
७.१३ अरब
७.१३ अरब
९.७२ अरब
९.७२ अरब
Cost of goods sold
१.३१ अरब
१.३१ अरब
१.६५ अरब
१.६५ अरब
Cost of revenue
१.३१ अरब
१.३१ अरब
१.६५ अरब
१.६५ अरब
Research and development expenses
२.९३ अरब
२.९३ अरब
१.५४ अरब
१.५४ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२.८० अरब
२.८० अरब
३.११ अरब
३.११ अरब
Operating expense
४.३८ अरब
४.३८ अरब
४.७७ अरब
४.७७ अरब
Total operating expenses
५.६९ अरब
५.६९ अरब
६.४२ अरब
६.४२ अरब
Operating income
१.४४ अरब
१.४४ अरब
३.३१ अरब
३.३१ अरब
Other non operating income
९.८० करोड
९.८० करोड
७.६६ करोड
७.६६ करोड
EBT including unusual items
४८.८२ करोड
४८.८२ करोड
३.६७ अरब
३.६७ अरब
EBT excluding unusual items
१.५५ अरब
१.५५ अरब
३.५६ अरब
३.५६ अरब
Income tax expense
३२.३८ करोड
३२.३८ करोड
५९.८० करोड
५९.८० करोड
Effective tax rate
६६.३२%
६६.३२%
१६.२९%
१६.२९%
Other operating expenses
-१.३५ अरब
-१.३५ अरब
११.३२ करोड
११.३२ करोड
Net income
-५२.२६ करोड
-५२.२६ करोड
१.७२ अरब
१.७२ अरब
Net profit margin
-७.३३%
-७.३३%
१७.६६%
१७.६६%
Earnings per share
-
-
-
-
Interest and investment income
१९.६४ करोड
१९.६४ करोड
२५.०१ करोड
२५.०१ करोड
Interest expense
-७.७६ करोड
-७.७६ करोड
-८.४८ करोड
-८.४८ करोड
Net interest expenses
११.८८ करोड
११.८८ करोड
१६.५३ करोड
१६.५३ करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
१.६६ अरब
१.६६ अरब
३.५७ अरब
३.५७ अरब
Gain or loss from assets sale
-५५.८५ लाख
-५५.८५ लाख
-
-
AI content may include mistakes. Learn more
Google एपहरू